GUIDELINE REVIEW
Guideline review: management of invasive meningococcal disease, SIGN
Correspondence to:
J H Baumer, Little Luson, Nr Yealmpton, Plymouth PL8 2JD, UK; harry@luson.plus.com
| The first 150 words of the full text of this article appear below. |
Despite advances in prevention and management, invasive meningococcal disease remains an important cause of mortality and morbidity in the UK; it is the most common infectious cause of death in children aged between 1 and 5 years. The overall case fatality rate in England, Wales and Northern Ireland in 2002–2003 was 5.6%, with an annual rate of confirmed meningococcal disease of 52.9 per 100 000 in the under 1 year age group, 18.8 per 100 000 in the 1–4 years age group, and 3.1 per 100 000 in the 5–14 years age group.1 Since 1999, when specific immunisation was introduced, the number of cases due to meningococcus serogroup C has reduced considerably. Over the same time there has been a slight reduction in the number of cases caused by the B serogroup.
A widely used management algorithm was published in 1999 by the St Marys Paediatric Intensive Care Unit, based
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.



